JOSEPH O'DONOGHUE

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    EJNMMI Res 3:42. 2013
  2. ncbi request reprint Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
  3. ncbi request reprint Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy
    JOSEPH O'DONOGHUE
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 19:378-87. 2004
  4. ncbi request reprint Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 61:1493-502. 2005
  5. ncbi request reprint A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia
    Bixiu Wen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, New York 10021, USA
    Eur J Nucl Med Mol Imaging 31:1530-8. 2004
  6. pmc Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia
    HyungJoon Cho
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neoplasia 11:247-59, 2p following 259. 2009
  7. ncbi request reprint Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning
    Pat Zanzonico
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Eur J Nucl Med Mol Imaging 31:117-28. 2004
  8. pmc Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging
    Wenli Wang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Phys Med Biol 54:3083-99. 2009
  9. doi request reprint Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Radiology, Weill Cornell Medical College, New York, NY Algeta ASA, Oslo, Norway Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Cornell Medical College, New York, NY
    Health Phys 106:494-504. 2014
  10. pmc In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression
    Sean Carlin
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 36:821-31. 2009

Collaborators

Detail Information

Publications16

  1. pmc Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    EJNMMI Res 3:42. 2013
    ....
  2. ncbi request reprint Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
    ..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized...
  3. ncbi request reprint Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy
    JOSEPH O'DONOGHUE
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 19:378-87. 2004
    ..Animal studies have also clarified the dose-dependency of the time to expression of radiation nephropathy and have indicated that radiation nephropathy may be alleviated by pharmacological means...
  4. ncbi request reprint Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 61:1493-502. 2005
    ..To compare two potential positron emission tomography (PET) tracers of tumor hypoxia in an animal model...
  5. ncbi request reprint A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia
    Bixiu Wen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, New York 10021, USA
    Eur J Nucl Med Mol Imaging 31:1530-8. 2004
    ..The purpose of this study was to develop and characterize a rodent tumor model with a reporter gene construct that would be transactivated by the hypoxia-inducible molecular switch, i.e., the upregulation of HIF-1...
  6. pmc Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia
    HyungJoon Cho
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neoplasia 11:247-59, 2p following 259. 2009
    ....
  7. ncbi request reprint Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning
    Pat Zanzonico
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Eur J Nucl Med Mol Imaging 31:117-28. 2004
    ....
  8. pmc Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging
    Wenli Wang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Phys Med Biol 54:3083-99. 2009
    ....
  9. doi request reprint Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Radiology, Weill Cornell Medical College, New York, NY Algeta ASA, Oslo, Norway Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Cornell Medical College, New York, NY
    Health Phys 106:494-504. 2014
    ..Subsequent studies have demonstrated significantly improved overall survival and very low toxicity, suggesting that ²²³Ra may provide a new standard of care for patients with CRPC and bone metastases...
  10. pmc In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression
    Sean Carlin
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 36:821-31. 2009
    ..To characterize a tumor model containing a hypoxia-inducible reporter gene and to demonstrate utility by comparison of reporter gene expression to the uptake and distribution of the hypoxia tracer (18)F-fluoromisonidazole ((18)F-FMISO)...
  11. pmc Image deconvolution in digital autoradiography: a preliminary study
    Mutian Zhang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Med Phys 35:522-30. 2008
    ..Digital autoradiograms following deconvolution show improved sharpness and contrast relative to the unprocessed autoradiograms...
  12. pmc Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats
    Rachel M Bartlett
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 53:1608-15. 2012
    ..The objective of this study was to determine whether kinetic analysis of dynamic (18)F-fluoromisonidazole data provides better discrimination of tumor hypoxia than methods based on a simple tissue-to-plasma ratio...
  13. pmc Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?
    Makiko Suehiro
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nucl Med Biol 36:477-87. 2009
    ....
  14. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  15. pmc Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Volkan Beylergil
    aDepartment of Radiology, Molecular Imaging and Therapy Service bDepartment of Medicine, Breast Cancer Medicine Service cHuman Oncology and Pathogenesis Program dDepartment of Medical Physics eRadiochemistry and Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center Departments of fRadiology gMedicine, Weill Cornell Medical College, New York, New York, USA
    Nucl Med Commun 34:1157-65. 2013
    ....
  16. pmc Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
    Peter M Smith-Jones
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    Nucl Med Biol 35:343-51. 2008
    ..The in vitro and in vivo behavior of the radiolabeled monoclonal antibody MORAb-003 was investigated as a prelude to a clinical trial...